Rating Change
Needham reiterated its Buy rating on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on October 16, 2026.
reiterateNASDAQ:NBIX
Needham Reiterates Buy Rating on Neurocrine Biosciences, Inc. (NBIX)
Needham reiterated its Buy rating on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on October 16, 2026.
At publication ·
What changed
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) · reiterate
- Firm
- Needham
- Rating
- Buy to Buy
- Price at event
- $135.71
- Market capitalization
- $15.4B
At a glance
Key takeaways
- Needham reiterated a Buy rating on Neurocrine Biosciences (NBIX) on October 16, 2026, with the stock trading at $135.71.
Market Context
Neurocrine Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $135.71 with a market capitalization of $15.4B. The stock has declined 4.0% over the past 52 weeks.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Neurocrine Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Neurocrine Biosciences, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 16, 2026 | Needham | Buy | N/A |
| Oct 12, 2026 | BMO Capital | Market Perform | N/A |
| Sep 29, 2026 | UBS | Buy | N/A |
| Sep 11, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Sep 08, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View NBIX Stock Page
Frequently Asked Questions
What does the Buy rating mean for NBIX?
A rating of Buy from Needham reflects the analyst's outlook on Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NBIX forecast page.